Longeveron Inc - Class A
Research Longeveron Inc - Class A (LGVN) on Bullrun: market cap USD 21.57M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLGVN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 21.57M
- Financial periodQ1 2026
- RevenueUSD 398.00K
- Net income-USD 4.74M
- Free cash flow-USD 4.39M
- Gross margin66.3%
Valuation Snapshot
latest market cap is USD 21.57M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.20M | -USD 22.70M | -USD 18.89M | 67.0% | -1.29 | USD 4.66M | USD 824.00K | USD 5.68M |
| FY2024 | USD 2.39M | -USD 15.97M | -USD 14.52M | 78.8% | -2.62 | USD 19.23M | USD 1.45M | USD 21.89M |
| FY2023 | USD 709.00K | -USD 21.41M | -USD 19.30M | 31.2% | -10.22 | USD 4.95M | USD 2.04M | USD 6.74M |
| FY2022 | USD 1.22M | -USD 18.84M | -USD 14.54M | 40.7% | -0.9 | USD 10.50M | USD 2.88M | USD 20.50M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 21.57M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 11.69M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 25.76M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 34.15M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 67.68M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 252.00M | n/a | n/a | n/a |
About Longeveron Inc - Class A
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Longeveron Inc - Class A's market cap?
Longeveron Inc - Class A's market capitalization is USD 21.57M.
What does Longeveron Inc - Class A do?
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.